We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Lays Out Weight of Evidence Guidelines for Fetal Toxicity in Oncology
FDA Lays Out Weight of Evidence Guidelines for Fetal Toxicity in Oncology
Cancer drug sponsors won’t have to do separate studies if they can demonstrate that the weight of evidence shows that a given drug is dangerous to developing babies, the FDA says in a final guidance document issued Thursday.